z-logo
open-access-imgOpen Access
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy
Author(s) -
Haixing Mai,
Mei Guo-Hui,
Fukun Zhao,
Botao Li,
Yongyong Tang,
Bin Zhang,
Xiaoqin Xu,
Lijun Chen
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.180609
Subject(s) - medicine , renal cell carcinoma , sorafenib , sunitinib , nephrectomy , clinical endpoint , urology , cytokine induced killer cell , progression free survival , gastroenterology , metastasis , oncology , retrospective cohort study , surgery , kidney , overall survival , hepatocellular carcinoma , cancer , immunology , clinical trial , immune system , cd3 , cd8
Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here